Cerebral Microbleeds in Autosomal Dominant Polycystic Kidney Disease

Li-Kai Tsai; Pei-Lung Chen; Hsin-Hsi Tsai; Ya-Fang Chen; Ping-Chun Wu; Jiann-Shing Jeng; Jenq-Wen Huang; Tzong-Shinn Chu; Juliana Tze-Wah Kao

doi:10.5853/jos.2019.02838

Letter to the Editor

Journal of Stroke 2020;22(1):153-156.

Published online: January 31, 2020

DOI: https://doi.org/10.5853/jos.2019.02838

Cerebral Microbleeds in Autosomal Dominant Polycystic Kidney Disease

Li-Kai Tsai^a, Pei-Lung Chen^b,^c, Hsin-Hsi Tsai^a,^d, Ya-Fang Chen^e,^f, Ping-Chun Wu^g, Jiann-Shing Jeng^a, Jenq-Wen Huang^h, Tzong-Shinn Chu^h, Juliana Tze-Wah Kao^h,ⁱ

^aDepartment of Neurology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

^bDepartment of Medical Genetics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

^cGraduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan

^dDepartment of Neurology, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan

^eDepartment of Medical Imaging, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

^fDepartment of Medical Imaging, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan

^gGraduate Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

^hDepartment of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

ⁱDepartment of Internal Medicine, FuJen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan

Correspondence: Juliana Tze-Wah Kao Department of Internal Medicine, FuJen Catholic University Hospital, Fu Jen Catholic University, No. 69, Guizi Road, Taishan District, New Taipei City 24352, Taiwan Tel: +886-2-29053957 Fax: +886-2-29896955 E-mail: twkao2@ntuh.gov.tw

This work was supported by grants from the National Taiwan University Hospital (108-S4110, 108-A147, and 201801072RSA-2-MQ4059).

The authors have no financial conflicts of interest.

Received October 22, 2019 Revised November 15, 2019 Accepted January 14, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dear Sir:

Autosomal dominant polycystic kidney disease (PKD) is characterized by multiple enlarged renal cysts that subsequently lead to renal insufficiency [1]. While PKD is associated with intracranial aneurysm [2], which reflects large artery anomalies, it remains unknown whether there is also abnormality in cerebral small vessels. The aim of this study was to investigate the prevalence and determinants of cerebral microbleeds (CMBs) in a cohort of patients with PKD.

Fifty-five consecutive PKD patients without past history of stroke, and 45 control subjects who visited the neurology outpatient clinics with no prior stroke or family history of PKD, were prospectively enrolled for brain magnetic resonance imaging (MRI), including susceptibility-weighted imaging (SWI). Twenty-two PKD patients (40%) received another follow-up brain MRI study. CMBs were defined as small, round or ovoid hypointensities with a diameter less than 1 cm on SWI [3]. A subgroup of patients with PKD underwent genetic testing using next-generation sequencing to screen the entire PKD1 and PKD2 genes. Fisher’s exact test and Student's t-test or Mann-Whitney U test were used to determine the differences between groups for categorical data and continuous data, respectively. The determinants for the presence of CMBs were analyzed using a logistic regression model. Two-tailed P-values of less than 0.05 were considered statistically significant (STATA software version 8.2, StataCorp., College Station, TX, USA). Detailed methods are available in Supplementary methods [1,3-12].

Comparison of the 55 PKD patients with the 45 control subjects (Supplementary Table 1) showed that PKD patients had a lower estimated glomerular filtration rate (eGFR) level than control subjects. More patients in the PKD group had CMB (27.3% vs. 6.7%, P=0.009), intracranial aneurysm (10.9% vs. 0%, P=0.031) and hypertension than in the control group. Among 15 PKD patients with CMBs (mean age, 58.4±10.8 years; range, 30 to 73), seven patients (46.7%) had CMBs located exclusively at the lobar regions, five (33.3%) had CMBs located exclusively at the deep regions and three (20%) had lobar and deep CMBs (mixed location). The number of CMBs for each patient ranged from 1 to 6, with a total count of 40 CMBs for all patients; 22 (55%) of the CMBs were in the lobar regions (12 in the frontal, five in temporal, four in occipital, and one in parietal regions) and 18 (45%) were in the deep regions (eight in the cerebellum, five in basal ganglion, three in brainstem, and two in thalamus) (Figure 1).

Comparing the characteristics of PKD patients with and without CMBs (Supplementary Table 2), PKD patients with CMBs were older than those without (58.4±10.8 years vs. 48.7±9.8 years, P=0.002). In univariable analysis of 100 patients and controls, age and the diagnosis of PKD were the positive determinants and eGFR level was a negative determinant for the detection of CMBs (Table 1). Using a multivariable logistic regression model, only older age (adjusted odds ratio [aOR], 1.09; 95% confidence interval [CI], 1.02 to 1.17) and the diagnosis of PKD (aOR, 7.28; 95% CI, 1.18 to 45.0) remained independent determinants for the presence of CMBs.

In 49 patients receiving genetic testing, 22 (44.9%) and 18 patients (36.7%) were found to have PKD1 and PKD2 gene causative variants, respectively (Figure 2). No significant genotype correlated with CMBs in PKD patients. In 22 PKD patients who received the second MRI study with an average follow-up period of 36.5±12.4 months, seven (31.8%) developed new CMBs. For 12 PKD patients with no CMBs noted on the first MRI study, only one (8.3%) had new CMBs on the follow-up MRI study; however, six of 10 PKD patients (60%) with CMBs on the initial MRI developed new CMBs (P=0.02). Patients with new CMBs during follow-up were older than those without new CMBs (60.9±8.4 years vs. 50.2±8.9 years, P=0.024).

The prevalence of CMBs in our PKD patients was about one-fourth (27.3%), much higher than that in the normal population of this study (6.7%). Multivariable analysis revealed that older age and PKD diagnosis were the independent determinants for the presence of CMBs. During long-term follow-up, about one-third (31.8%) of PKD patients also developed new CMBs. The present study demonstrates a novel vascular phenotype of PKD, i.e., CMBs, which indicates the relative structural fragility of cerebral small vessels in those with PKD.

Patients with cerebral small vessel disease (SVD) have been reported to more likely have CMBs. The present study is the first to demonstrate that those with PKD are prone to have CMBs. Other MRI markers found commonly in SVD, including an increase of white matter hyperintensity, the presence of lacune, and a high degree of enlarged perivascular space [3], were not features in PKD patients. The cerebral small vessel fragility in PKD might be the underlying pathophysiology that results in only CMB without any other parenchymal injury.

The distribution of CMBs in PKD patients were heterogeneous and found exclusively at lobar locations, exclusively deep and mixed regions in 46.7%, 33% and 20% of patients, respectively. In seven patients with exclusively lobar CMBs, three were younger than 55 years old and did not fulfill the Boston diagnostic criteria for cerebral amyloid angiopathy (CAA) [13]. Therefore, CAA is less likely in these relatively young patients when coexisting CAA is possible. Although chronic hypertension may be a risk factor for CMB formation in PKD patients, the fact that more than half of the CMBs were located in the lobar area suggests that factors other than hypertension may cause CMB formation. In addition, neither the presence of hypertension nor the eGFR level was significantly associated with CMBs in the multivariable model.

In summary, we report a novel phenotype of CMBs in patients with PKD that indicates the fragility of cerebral small vessels involving both deep penetrating and cortical-subcortical regions. The prevalence of CMBs is about one-fourth of PKD patients. Older age and the diagnosis of PKD are the only independent determinants of the occurrence of CMBs. Brain MRI studies in patients with PKD should emphasize the presence of not only intracranial aneurysm, but also CMBs.

Supplementary materials

Supplementary materials related to this article can be found online at https://doi.org/10.5853/jos.2019.02838.

Supplementary methods

jos-2019-02838-suppl1.pdf

Supplementary Table 1.

Characteristics of patients with and without polycystic kidney disease

jos-2019-02838-suppl2.pdf

Supplementary Table 2.

Characteristics of patients having polycystic kidney disease with and without cerebral microbleeds

jos-2019-02838-suppl3.pdf

Figure 1.

Patients with polycystic kidney disease (PKD) and having cerebral microbleeds (CMBs). (A) A 70-year-old woman had PKD with multiple cysts in bilateral kidney and liver (asterisks) noted by abdominal computed tomography (CT). The susceptibility-weighted imaging (SWI) shows a CMB (white arrow) in the left temporal area. The time-of-flight (TOF) image shows an intracranial aneurysm (black arrow) in the left distal internal carotid artery. (B) A 50-year-old man had PKD and the SWI shows a CMB (white arrow) in the right temporal area. The TOF image shows a fusiform aneurysm (black arrow) in the left anterior cerebral artery. (C) A 55-year-old woman had PKD and the SWI shows two CMBs (white arrows) in the right basal ganglion and thalamus. The TOF image does not show an aneurysm. Scale bar, 1 cm.

Figure 2.

Genotype-phenotype correlation in 49 patients with polycystic kidney disease (PKD). (A) Twenty-two (44.9%) and 18 (36.7%) patients were found to have PKD1 and PKD2 gene causative variants, respectively. (B, C) The risk of having cerebral microbleeds (CMBs) did not differ significantly by the presence of different causative genes (P=0.84) or variant types (P=0.5). (D) For PKD1 causative variants, no specific gene region (5’:1-6,000 vs. 3’:6,000-12,000) was associated with CMBs (P=0.62). (E) Among PKD patients who had CMBs and received a genetic study (n=13), patients with the PKD1 causative variant showed a trend to have a higher average number of CMBs than those with PKD2 causative variants (3.8±2.0 vs. 1.4±0.5, P=0.08). The total number of PKD patients with CMBs was relatively small (n=15), impeding a complete phenotype and genotype analysis.

Table 1.

Determinants of the presence of cerebral microbleeds using logistic regression analysis

Variable	Univariable analysis			Multivariable analysis
Variable	OR	P	95% CI	Adjusted OR	P	95% CI
Age (yr)	1.07	0.008	1.02-1.13	1.09	0.012	1.02-1.17
Male sex	1.54	0.412	0.55-4.35
Polycystic kidney disease	5.25	0.013	1.41-19.5	7.28	0.033	1.18-45.0
Hypertension	3.02	0.069	0.92-9.97	1.04	0.962	0.25-4.31
eGFR (mL/min/1.73 m²)	0.98	0.002	0.96-0.99	0.997	0.739	0.98-1.02

The model for multivariate analysis includes age, polycystic kidney disease, hypertension, and eGFR.

OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate.

References

1. Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet 2019;393:919-935.

2. Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 2011;42:204-206.

3. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822-838.

4. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 2018;71:1269-1324.

5. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A.

6. Tsai HH, Pasi M, Tsai LK, Chen YF, Lee BC, Tang SC, et al. Microangiopathy underlying mixed-location intracerebral hemorrhages/microbleeds: a PiB-PET study. Neurology 2019;92:e774-e781.

7. Tsai HH, Tsai LK, Chen YF, Tang SC, Lee BC, Yen RF, et al. Correlation of cerebral microbleed distribution to amyloid burden in patients with primary intracerebral hemorrhage. Sci Rep 2017;7:44715.

8. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer‘s dementia and normal aging. AJR Am J Roentgenol 1987;149:351-356.

9. Pasi M, Boulouis G, Fotiadis P, Auriel E, Charidimou A, Haley K, et al. Distribution of lacunes in cerebral amyloid angiopathy and hypertensive small vessel disease. Neurology 2017;88:2162-2168.

10. Charidimou A, Boulouis G, Pasi M, Auriel E, van Etten ES, Haley K, et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 2017;88:1157-1164.

11. Wu CC, Lin YH, Liu TC, Lin KN, Yang WS, Hsu CJ, et al. Identifying children with poor cochlear implantation outcomes using massively parallel sequencing. Medicine (Baltimore) 2015;94:e1073.

12. Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 2003;361:2196-2201.

13. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke 2018;49:491-497.

	Editorial Office Department of Neurology, Asan Medical Center,Ulsan University College of Medicine 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Submission, status and progress, etc ⟫ E-mail: editor@j-stroke.org Website and system ⟫ E-mail: journal@m2community.co.kr Publishing company ⟫ E-mail: ka72sus@smileml.com
	Copyright © 2024 by Korean Stroke Society.